etal congenital bradyarrhythmia is an uncommon but life-threatening disease, especially in the case of complete atrioventricular block (CAVB), which has a poor prognosis because of fetal hydrops, endocardial fibroelastosis and late-onset dilated cardiomyopathy. 1- 9 Predominantly untreated CAVB has a significant mortality rate of 14-34%, while congenital CAVB is irreversible and requires a pacemaker in approximately 66% of cases after birth. 10 The association of CAVB with maternal anti-Ro/Sjögren's syndrome A (SSA) antibodies is well established, but the trigger for the maternal antibody interaction with the fetal Ro particle is unknown in some cases of antibody-exposed babies. 2,7-9,11, 12 There is limited evidence for the clinical efficacy of transplacental treatment of congenital AVB. [13] [14] [15] [16] [17] [18] [19] Steroids and i.v. immunoglobulins are given as anti-inflammatory treatment, while β-sympathomimetics are used for fetal pacing. 20 A recent
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cohort study found an improved survival rate of >90% with initiation of maternal high-dose dexamethasone at the time of CAVB detection, and maintenance of this drug during pregnancy with use of β-sympathomimetics to keep fetal heart rates at >55 beats/min. 9, 21 It was also suggested that prolonged use of dexamethasone might render fetuses with congenital CAVB less likely to develop the additional manifestations of myocarditis, cardiomyopathy, and hydrops fetalis, thus improving the overall outcome. Use of steroids, however, is controversial because of the potential risks for the fetus, including problems with neurological development, growth retardation, and oligohydramnios. [22] [23] [24] [25] Few large studies of fetal congenital bradyarrhythmia have been performed in Japan. The aims of the present study were to determine the features of fetal congenital bradyarrhythmia in Japan, and to examine the effects and risks of transplacental treatment for this condition.
Methods

Subjects
Data were collected using questionnaires sent to Departments of Perinatology and Pediatric Cardiology at 750 institutions in Japan over 7 years (2002-2008) . The response rate was 60.7% (455 institutions). Fetal bradyarrhythmia was defined as ventricular heart rate <100 beats/min at the time of diagnosis. 4 The following perinatal data were also collected: gestational age at diagnosis and delivery, presence or absence of a congenital heart defect (CHD), type of bradyarrhythmia, method of diagnosis, presence or absence of maternal autoantibodies such as anti-Ro/SSA antibodies, presence or absence of fetal hydrops, presence or absence of fetal myocardial dysfunction, fetal ventricular and atrial heart rate at presentation, prenatal treatment, mode of delivery, and outcome. Adverse effects related to prenatal treatment were also evaluated.
Statistical Analysis
Statistical analysis was performed using STATA 11.1 (StataCorp, College Station, TX, USA) and JMP 9 (SAS Institute, Cary, NC, USA). Data are presented as mean ± SD or number of patients and were analyzed using Student's t-test. Categorical variables were evaluated on chi-square test and Fisher's exact test. Logistic regression was used to adjust for baseline variables known to be associated with fetal ventricular heart rate, fetal hydrops, fetal myocardial dysfunction, and maternal anti-Ro/SSA antibody. Time to fetal or neonatal death was analyzed using the Kaplan-Meier method with a log-rank test and a Cox proportional hazard model. P<0.05 was considered significant.
Results
Baseline Characteristics
A total of 128 cases were registered from 52 institutions during 7 years (2002) (2003) (2004) (2005) (2006) (2007) (2008) . All cases of fetal bradyarrhythmia were diagnosed during fetal life using echocardiography. In 8 cases, magnetocardiography was performed due to fetal bradyarrhythmia and family history of long QT syndrome (LQTS). Of the 128 fetuses, 38 (29.7%) had CHD, 15 had left atrial isomerism, 1 had right atrial isomerism, 5 had atrioventricular septal defect, 4 had corrected transposition of the great arteries, 4 had pulmonary stenosis, and 9 had other conditions. Patent ductus arteriosus and atrial septal defect were categorized as an absence of CHD. Ninety fetuses (70.3%) had a structurally normal heart, of whom 61 had CAVB, 16 had second-degree AVB, 8 had sinus bradycardia, 3 had sick sinus syndrome. Nine LQTS cases occurred in combination with another condition.
CAVB
Of the 61 fetuses with a structurally normal heart and CAVB (Table 1) , 38 received transplacental medication. No fetus showed improvement of heart block. Monotherapy with β-sympathomimetics was given in 11 cases, steroids were given in 5 cases, and combination therapy with these agents was used in 22 cases. No transplacental medication was given in 23 cases. Ritodrine hydrochloride was used as the β-sympathomimetic agent. Steroids tended to be used in fetuses that were positive for maternal anti-Ro/SSA antibody throughout pregnancy, but the chosen steroid differed among institutions. Maternal i.v. immunoglobulin was not used. After birth, a pacemaker was implanted based on the Japanese guidelines of syncope, ventricular heart rate <50 beats/min, decreased cardiac function, LQTS, and a sudden pause longer than 2-3-fold the regular ventricular heart rate. The anti-Ro/SSA antibody-positive rate was significantly higher in fetuses treated with transplacental medication compared to those who did not receive this medication (76.3% vs. 47.8%; P=0.031). Gestational age at diagnosis was significantly lower in those receiving transplacental medication (24.0 weeks vs. 28.3 weeks; P=0.003). Fetal ventricular heart rate at diagnosis did not differ between the 2 groups, but the ventricular heart rate was significantly lower in fetuses treated with transplacental medication (56 beats/min vs. 63 beats/min; P=0.034). Birth weight was also significantly lower in fetuses treated with transplacental medication (2,120 g vs. 2,528 g; P=0.006). Gestational age at delivery, neonatal survival rate, and pacemaker implantation rate did not differ between the 2 groups.
Multivariate analysis was performed with adjustment for baseline variables with a known association with fetal ventricular heart rate, fetal hydrops, fetal myocardial dysfunction, and the presence of maternal anti-Ro/SSA antibodies ( Tables 2-4) . In this analysis, β-sympathomimetic treatment was significantly associated with improved bradycardia (odds ratio [OR], 49.02; 95% confidence interval [CI]: 5.18-464.02; P<0.001), whereas steroids were ineffective, and no evidence of a synergistic effect was obtained. The presence of maternal anti-Ro/ SSA antibodies may inhibit improvement of bradycardia, but this effect was not significant (OR, 0.22; 95%CI: 0.04-1.36; P=0.105). Drug therapy had no significant effect on survival. Fetal ventricular heart rate and the presence of maternal antiRo/SSA antibodies also had no influence on prognosis, but fetal hydrops was associated with a 14-fold increased risk of perinatal death (hazard ratio [HR], 13.84; 95%CI: 3.12-61.44; P=0.001).
Kaplan-Meier survival curves are shown in Figure. The primary endpoint was intrauterine death or neonatal death. Beta-sympathomimetic treatment was not associated with improved prognosis. Steroid also did not improve the prognosis (HR, 0.56; 95%CI: 0.20-1.58; P=0.273). Fetal myocardial dysfunction was a significant risk factor for fetal hydrops (OR, 5.71; 95%CI: 1.14-28.62; P=0.034). Fetal ventricular heart rate and the presence of maternal anti-Ro/SSA antibodies were not associated with fetal hydrops. Beta-sympathomimetic treatment did not inhibit development of fetal hydrops. Steroids tended to inhibit fetal hydrops, but again this effect was not Logistic regression was used to adjust for baseline variables known to be associated with fetal ventricular heart rate, fetal hydrops, fetal myocardial dysfunction, and maternal anti-Ro/SSA antibody. OR, odds ratio; CI, confidence interval; SSA, Sjögren's syndrome A. Logistic regression was used to adjust for baseline variables known to be associated with fetal ventricular heart rate, fetal hydrops, fetal myocardial dysfunction, and maternal anti-Ro/SSA antibody. HR, hazard ratio; CI, confidence interval; SSA, Sjögren's syndrome A. 
Second-Degree AVB With Bradycardia
Of the 90 fetuses with a structurally normal heart, second-degree AVB was present in 16 cases ( Table 5) . Transplacental medication was given in 8 of these cases: β-sympathomimetic monotherapy in 4, steroids in 3, and a combination of these therapies in 1. In the 8 medication cases, fetal ventricular heart rate at diagnosis was significantly lower than that in the nonmedication cases (70 beats/min vs. 79 beats/min; P=0.017).
No other clinical characteristics differed significantly between the 2 groups. Of the 8 medicated fetuses, 3 developed CAVB, 3 maintained second-degree AVB, 1 improved to first-degree AVB, and 1 had no AVB at the time of delivery. Of the 8 nonmedicated fetuses, 2 developed CAVB, 3 maintained seconddegree AVB, and 3 had no AVB at the time of delivery. Survival rate did not differ between the groups (87.5%).
Adverse Effects of Transplacental Treatment
Treatment-related adverse events were examined in the 63 fetuses with a structurally normal heart and no fetal hydrops ( Table 6 ). Steroids were given in 23 cases, drugs other than steroids were given in 10 cases, and no treatment was given in 30 cases. Gestational age at delivery did not differ among these 3 groups. In the steroid group, birth weight was significantly lower than in the non-treatment group (2,201 g vs. Data given as mean ± SD or n (%). † For fetuses without fetal hydrops and with a structurally normal heart. *P<0.05 (Student's t-test). CAVB, complete atrioventricular block; AVB, atrioventricular block. 
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LQTS
Of the 90 fetuses with a structurally normal heart, 9 (10.0%) were diagnosed with LQTS, including 4 diagnosed on electrocardiography after birth and 5 diagnosed on magnetocardiography during fetal life. The background of the LQTS fetuses included a family history of LQTS (n=2), maternal anti-Ro/ SSA antibody (n=2), fetal hydrops (n=3), myocardial dysfunction (n=2), CAVB (n=6), second-degree AVB with bradycardia (n=1), and sinus bradycardia (n=2). In 4 of the 9 cases of LQTS, emergency cesarean section was performed because of fetal ventricular tachycardia/torsades de pointes (VT/TdP) at 33-36 weeks of gestation. In 2 of the 9 cases, fetal hydrops caused neonate death.
Discussion
This is the first large-scale study to investigate the effects and risks of transplacental treatment for fetal congenital bradyarrhythmia in Japan. The results indicate that fetal hydrops is associated with a 14-fold increased risk of perinatal death, and that fetal myocardial dysfunction is a significant risk factor for fetal hydrops. Fetal ventricular heart rate and the presence of maternal anti-Ro/SSA antibodies were not associated with neonatal prognosis. Beta-sympathomimetics improved bradycardia, but survival rate did not differ significantly with regard to transplacental medication. Maternal and fetal adverse effects were observed in cases of steroid use. In particular, fetal growth restriction increased significantly after steroid use >10 weeks.
Evaluation of Anti-Ro/SSA Antibodies
Ro/SSA is one of the major immunogenic ribonucleoproteins, and antibodies against these proteins are found in a number of connective diseases, especially in Sjögren's syndrome (SS) and systemic lupus erythematosus (SLE). Anti-Ro/SSA antibodies are detected in 60-90% of SS cases and in 30-50% of SLE cases. 26, 27 Interestingly, these antibodies are relatively common and are detected in 1-2% of randomly tested pregnant women. 28 Currently, the outcome of anti-Ro/SSA-positive pregnancies is very good when prospectively followed by multidisciplinary teams with experience in this field. 1 Transplacental passage of anti-Ro/SSA antibodies from mother to fetus, however, is associated with a risk of development of neonatal lupus erythematosus (NLE). 2,11,12 NLE is an uncommon but life-threatening disease of the fetus and neonate, with important cardiac complications of CAVB, sinus bradycardia, QTc interval prolongation, endocardial fibroelastosis, and late-onset dilated cardiomyopathy. 3-5 Congenital CAVB develops in 1-5% of anti-Ro/SSA antibody-positive pregnancies, typically between 18 and 24 weeks of gestational age. Predominantly untreated CAVB has a mortality rate of 14-34%, 1-9 consistent with the untreated CAVB mortality rate of 26% in the current study. The association of NLE with maternal anti-Ro/SSA antibodies is well established, but the trigger of the maternal antibody interaction with the fetal Ro particle is unclear in some antibody-exposed babies. The percentage of maternal anti-Ro/SSA antibody-positive fetuses with CAVB diagnosed in utero is unknown. Brucato et al and Jaeggi et al found maternal antiRo/SSA antibodies in 92% of 37 CAVB cases, 7,9 whereas in the present study maternal anti-Ro/SSA antibodies were detected in only 66% of 61 CAVB fetuses with a structurally normal heart. Jaeggi et al also reported that CAVB occurred in 5% of prospectively screened pregnancies with anti-Ro/ SSA ELISA levels >100 U/ml, but did not occur in pregnancies with levels <50 U/ml. 6 Approximately two-thirds of antiRo/SSA antibody-positive mothers had low anti-Ro/SSA levels and probably little risk of development of fetal cardiac NLE. 8 It is unclear why the anti-Ro/SSA-positive rate in the present study was lower than in other reports. It is unlikely to be due to the sensitivity of the laboratory methods, but it is possible that other undetectable antibodies associated with congenital AVB are present in the Japanese population. Brucato et al and Lopes et al found similar mortality rates in the anti-Ro/SSA-positive and -negative groups, 7,8 and in the present multivariate analysis anti-Ro/SSA antibodies were not associated with prognosis.
Benefits and Risks of Transplacental Treatment
Congenital AVB is a progressively developing disease that evolves through 2 fundamental phases: an early phase characterized by the occurrence of still reversible AV conduction abnormalities (first-or second-degree AVB) and a final phase in which development of irreversible damage of the conduction system leads to the appearance of CAVB. 29 The specific pathogenetic mechanisms involved in the 2 phases have not been clarified, but there are 2 main theories. The first is based on an inflammatory-driven injury elicited by interaction between anti-Ro/SSA antibodies and specific antigens expressed in the conduction tissue of the fetal heart (inflammatory theory). The second theory involves electrophysiologic interference of antiRo/SSA antibodies with heart conduction (electrophysiological theory). 20 Consistent with these respective theories, steroids and i.v. immunoglobulins are used for anti-inflammatory treatment, while β-sympathomimetics are given for fetal pacing.
Several studies have found that a ventricular heart rate <55 beats/min is a risk factor for fetal and neonatal death, 4,14 and have recommended transplacental treatment with β-sympathomimetics to increase the heart rate. Jaeggi et al and Maeno et al, however, found that fetuses with CAVB without CHD and with a ventricular heart rate of <55 beats/min were not at risk. 30, 31 In the present study, fetal ventricular heart rate did not influence fetal hydrops and prognosis, but treatment with a β-sympathomimetic agent was significantly associated with improved bradycardia.
To date, evidence of clinical efficacy of transplacental treatment has been limited to cases of congenital AVB. 13- 19 Jaeggi et al reported a significant improvement in the outcome of fetal CAVB simultaneously with the introduction of routine perinatal treatment guidelines in 1997. 9 Hutter et al obtained an improved survival rate of >90% by initiation of maternal high-dose dexamethasone at the time of CAVB detection and maintenance of this dose during pregnancy, with addition of β-sympathomimetics to keep the fetal heart rate above 55 beats/min. 21 It was also suggested that prolonged use of dexamethasone might render a fetus with congenital CAVB less likely to develop additional manifestations of cardiac NLE such as myocarditis, cardiomyopathy, and hydrops fetalis, thus improving the overall outcome. The present findings suggest that use of steroids might render the affected fetus less likely to develop fetal hydrops, but that the neonatal survival rate improved only to 79%. The reason for the relatively bad prognosis in the present study may have been the difference in the rate of fetal hydrops compared to the Hutter et al study (42% vs. 10%). Undetectable autoantibodies or virus infection may be related to the increased rate of fetal hydrops in the Japanese population. Furthermore, Hutter et al initiated maternal high-dose dexamethasone at the time of CAVB diagnosis, at a mean gestational age of 24 weeks. The mean age of diagnosis was similar in the present study, but mean gestational age at which steroids were started was 26 weeks. In addition, the percentage of steroids used in transplacental treatment was Treatment for Fetal Congenital Bradyarrhythmia lower in the present patients (71% vs. 95%). These findings suggest that sufficient steroid dose at an early stage is very important to prevent fetal hydrops and to improve prognosis.
Use of steroids is controversial because of the potential risks for the fetus and mother, including problems with fetal growth restriction, oligohydramnios, and neurological development. Animal models suggest that repeated antenatal steroid doses can interfere with the growth and development of the immature brain, and human studies suggest that antenatal and postnatal dexamethasone may negatively affect a child's neuropsychological development. 22-24 In contrast, Brucato et al found no negative effects on neuropsychological development and intelligence in a cohort of preschool-and school-age children with CAVB who had been prenatally exposed to maternal antiRo antibodies and prolonged dexamethasone treatment. 25 The association of fetal growth restriction and oligohydramnios with antenatal steroids is well established, but the amount and length of steroid treatment that can be used safely is unclear. We note that development of fetal growth restriction and oligohydramnios are dose-related complications of steroids. Consequently, we recommend limiting steroid use to <10 weeks to avoid maternal and fetal adverse effects.
Prevention of Progression to Congenital CAVB
There are many case reports describing prevention of congenital CAVB, and first-or second-degree AVB is also relatively common and often normalizes spontaneously before or soon after delivery. 32 Recent prospective studies suggest that steroids and i.v. immunoglobulins are not beneficial for preventing progression to congenital AVB. 33, 34 Similarly, the present study found a lack of superiority of transplacental treatment for second-degree AVB with bradyarrhythmia.
LQTS
Recent evidence has shown that anti-Ro/SSA antibodies are associated with prolongation of the QTc interval. 35 Although the exact arrhythmogenic mechanisms have not been clarified, anti-Ro/SSA antibodies may trigger rhythm disturbances through inhibition of cross-reactions with several cardiac ionic channels, including calcium channels and the hERG potassium channel. 36,37 Beta-sympathomimetics may trigger life-threatening arrhythmia such as VT/TdP in patients with LQTS, and therefore use of these drugs should be avoided in fetuses with QTc interval prolongation. 38, 39 In the present study, in 4 of the 9 LQTS cases, emergency cesarean section was performed because of fetal VT/TdP at 33-36 weeks of gestational age. Oka et al also recently described atrioventricular block-induced TdP. 40 With this background, we recommend avoidance of β-sympathomimetics in a fetus with a heart rate >55 beats/min. Furthermore, assessment of QTc interval prolongation on magnetocardiography may be required to evaluate the risk of fetal congenital bradyarrhythmia.
Study Limitations
There were several limitations in the present study due to retrospective data selection bias and the relatively small sample size. The nature of a multicenter retrospective observational study using a questionnaire is such that the clinical data obtained vary among cases, so treatment bias may exist. Only ritodrine hydrochloride was used as β-sympathomimetic treatment, but was given in cases involving fetal heart rate >55 beats/min at some institutions, while dexamethasone, betamethasone and prednisolone were used as steroids at different doses among institutions. The follow-up period after birth was insufficient to permit analysis of long-term morbidity and mortality, and this prevented evaluation of potential long-term benefits and risks of transplacental medication. Finally, the sample size might have been too small to detect the effects of steroids on fetal congenital bradyarrhythmia. The steroid effect may become significant in a study with a higher number of cases.
Guidelines are required for transplacental treatment of fetal congenital bradyarrhythmia and follow-up after birth. We expect to analyze long-term outcome of fetal congenital bradyarrhythmia in a future study. Further large prospective studies are also needed to establish the most appropriate treatment strategies in Japan.
Conclusion
Beta-sympathomimetics improved bradycardia, but survival rate did not differ significantly in fetuses treated with and without transplacental medication. We recommend limiting steroid use to <10 weeks to avoid maternal and fetal adverse effects, with fetal growth restriction and oligohydramnios being of particular concern.
